New diabetes clinical trial: Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets
Published on: November 04, 2022 at 11:00AM
Condition: Type 2 Diabetes Mellitus in Obese
Interventions: Drug: Semaglutide Pen Injector [Ozempic]; Dietary Supplement: Very-low Calorie Diet
Sponsors: University of Nottingham; Medical Research Council
Recruiting
https://ift.tt/3pHRSVK
Condition: Type 2 Diabetes Mellitus in Obese
Interventions: Drug: Semaglutide Pen Injector [Ozempic]; Dietary Supplement: Very-low Calorie Diet
Sponsors: University of Nottingham; Medical Research Council
Recruiting
https://ift.tt/3pHRSVK
Comments
Post a Comment